Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Signal Detection of Adverse Events Associated with Trastuzumab in a Cohort of Elderly Patients with Breast Cancer

The Oncologist(2022)10.1093/oncolo/oyac059Source: DataRank Database

Signal Detection of Adverse Events Associated with Trastuzumab in a Cohort of Elderly Patients with Breast Cancer is a research paper published in The Oncologist (2022). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.19)OA: goldTopics (37)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Sharon H. Giordano ORCID,Lin‐Na Chou ORCID,Xiaoying Yu ORCID,Yong‐Fang Kuo ORCID,Efstathia Polychronopoulou ORCID

Live enrichment

PubMed:35438771 PMC:PMC9177105 OpenAlex:https://openalex.org/W4224281731

Cancer Prevention and Research Institute of Texas

Grant: RP160674

Komen Foundation

Grant: SAC150061

National Cancer Institute

Grant: P30 CA016672

NICHD NIH HHS

Grant: K12 HD052023

National Institutes of Health

Grant: 3P30CA016672-41S4

Cancer Center Support (CORE) Grant

National Institutes of Health

FWCI

0.19

Citation Percentile

0.5%

Citation Trend

2023

2026

goldLicense: CC BY NC

journalhttps://academic.oup.com/oncolo/article-pdf/27/6/434/43984386/oyac059.pdf

publisherhttps://academic.oup.com/oncolo/article-pdf/27/6/434/43984386/oyac059.pdf

journalhttps://doi.org/10.1093/oncolo/oyac059

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35438771

repositoryhttps://digitalcommons.library.tmc.edu/uthgsbs_docs/2851

Fields of Study

HER2/EGFR in Cancer ResearchPharmacovigilance and Adverse Drug ReactionsAdvanced Breast Cancer Therapies03 medical and health sciences0302 clinical medicine

MeSH Terms

TrastuzumabAgedBreast NeoplasmsFemaleMedicareHumansUnited StatesCohort StudiesDrug-Related Side Effects and Adverse Reactions

Keywords

MedicineTrastuzumabBreast cancerAdverse effectPropensity score matchingInternal medicineOncologyCohortPoisson regressionCancerPopulationSignal detectionDrug safetyAdverse drug reactionsPharmacovigilanceCohort StudiesDrug-Related Side Effects and Adverse ReactionsHumansBreast NeoplasmsFemaleMedicareUnited StatesAged

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being